瑞舒伐他汀对急性冠脉综合征细胞间粘附因子-1和高敏C反应蛋白的影响  

Effects of Rosuvastatin on Plasma levels of ICAM-1 and hs-CRP in Patients with Acute Coronary Syndrome

作　　者：刘寓[1] 王娟[2] 杨均[1] 

机构地区：[1]湖北医药学院附属人民医院输血科,湖北十堰442000 [2]湖北医药学院附属人民医院检验科,湖北十堰442000

出　　处：《现代生物医学进展》2010年第23期4524-4525,共2页Progress in Modern Biomedicine

摘　　要：目的:观察瑞舒伐他汀对急性冠脉综合征(Acute Coronary Syndrome,ACS)患者细胞间粘附因子-1(Intercellular adhesionmolecule-1,ICAM-1)和高敏C反应蛋白(Hi-sensitive C-reactive protein,hs-CRP)水平的影响。方法:将96例急性冠脉综合征患者随机分为他汀组和常规对照组,常规对照组仅给予常规治疗,他汀组在常规组基础上每日加服一次瑞舒伐他汀10 mg,疗程4周,测定两组患者治疗前后ICAM-1和hs-CRP水平的变化。结果:4周后,他汀组低密度脂蛋白胆固醇(Low densitylipoprotein-cholesterol,LDL-C)、hs-CRP、ICAM-1均较治疗前明显降低(P<0.01,P<0.05),且较常规组治疗后低(P<0.05)。结论:瑞舒伐他汀治疗ACS患者,在有效调脂的同时可显著降低ICAM-1和hs-CRP的水平,抑制炎症反应,有利于动脉粥样硬化斑块的稳定。Objective：To observe the effects of Rosuvastatin on plasma levels of Intercellular adhesion molecule-1（ICAM-1） and Hi-sensitive C-reactive protein（hs-CRP）in Patients with Acute Coronary Syndrome（ACS）.Methods：96 patients of acute coronary syn-drome were selected and separated into two groups randomly：statin group and routine group.The patients in statin group were treated with Rosuvastain 10 mg/day besides conventional therapy,the patients in routine group were treated only with conventional therapy.The change of ICAM-1,and hs-CRP were measured before and after 4 weeks treatment.Results：The plasma levels of Low density lipopro-tein-cholesterol（LDL-C）,ICAM-1 and hs-CRP in statin group were decreased significantly（P0.01 or P0.05）after 4 weeks.the plasma levels of LDL-C,ICAM-1 and hs-CRP in statin group were lower than routine group after 4 weeks treatment（P0.05）.Conclusion：Treat-ments with Rosuvastatin could reduce the levels of ICAM-1 and hs-CRP and improved the function of coagulation system by the non-lipid-lowering with the lipid-lowering,thus it promotes the stabilization of atherosclerotic plaque.

关 键 词：瑞舒伐他汀 急性冠脉综合征 高敏C反应蛋白 细胞间粘附因子-1 

分 类 号：R541.4[医药卫生—心血管疾病] R972.3[医药卫生—内科学]